Search

everythinglearnresearchcommunity

for

Search:↓

A 28-year-old male reported significant hair regrowth using 5mg minoxidil and 0.5mg dutasteride over five months, with occasional ketoconazole use. Users discussed side effects like stuffy nose and low libido, and shared experiences with different hair loss treatments.

Mesotherapy for hair loss, including treatments like finasteride and dutasteride, is discussed, with some users reporting pain and mixed results. Alternatives like PRP injections and topical treatments such as minoxidil, RU58841, and tretinoin are also mentioned as effective options.

The conversation discusses a hair loss treatment regimen involving a homemade topical solution of Minoxidil and Tretinoin, combined with Finasteride and microneedling. Users share advice on Tretinoin application, emphasizing gradual use to avoid skin irritation.

The conversation discusses hair loss treatments using oral minoxidil, oral dutasteride, and mesotherapy dutasteride, showing impressive 6-month results. The user wishes these treatments were available in the U.S.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The user shared progress pictures after 5 months of Dutasteride Mesotherapy for hair loss. Commenters noted no visible change or worsening hair condition.

Men discussing hair loss treatments, including bicalutamide, cyproterone acetate, dutasteride, minoxidil, and RU58841. They share experiences and concerns about side effects like infertility, liver health, and feminization.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

A user's experience using dutasteride, minoxidil, ketoconazole, vitamin D, scalp massage, exercise, and avoiding vaping and 2-in-1 shampoo/conditioner to treat hair loss; they also discussed the side effects of finasteride.

The conversation discusses using topical cetirizine as a treatment for androgenetic alopecia (hair loss). Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Eucapill 2% used for 1 month reduced shedding from 200 to 10/20 hairs daily with no side effects. Finasteride caused side effects like ED and watery semen.

The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.

Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.

Topical dutasteride may not significantly reduce hair loss and could potentially increase testosterone, leading to further hair loss. Users report side effects like mood changes, sleep issues, and severe side effects, with no significant progress in hair regrowth.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

The user is using a hair recovery treatment with 0.5 mg dutasteride, 5 mg biotin, 5% topical minoxidil, and dermarolling twice a week. They are considering using a 1.5 mm dermaroller and red light therapy.

The conversation discusses treating male pattern baldness in a transgender woman using cyproterone acetate, finasteride, and biotin. The original poster shared their experience for others who might be in a similar situation.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

After over a year of treatment with daily oral dutasteride and minoxidil, plus injected dutasteride every 6 months, the user is happy with the increased thickness of their hair and improved self-esteem, although scalp visibility remains. They encourage others to follow similar treatments for long-term hair maintenance.

Dutasteride and finasteride mesotherapy may have fewer side effects like erectile dysfunction and libido loss compared to oral treatments, but it's less effective and more costly. Few people discuss it, and experiences with mesotherapy are limited.

Clascoterone is suggested as an alternative for those who experience side effects from finasteride and dutasteride. It is not widely available yet, but some users are obtaining it from compounding pharmacies or suppliers like Echemi.

The user has been using oral minoxidil and topical finasteride for over a year with good results but is considering adding mesotherapy with dutasteride due to concerns about side effects and is seeking advice. Another user suggests continuing with oral finasteride or dutasteride, while another supports mesotherapy for its benefits and professional oversight.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The user is experiencing hair loss despite using finasteride three times a week due to side effects and is considering alternatives like topical finasteride, estrogen blockers, or dutasteride. They are also interested in potential treatments like GT20029 and pyrilutamide.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.